Patrick Wood
Stock Analyst at Morgan Stanley
(0.51)
# 3,850
Out of 4,827 analysts
87
Total ratings
23.08%
Success rate
-14.54%
Average return
Main Sectors:
Stocks Rated by Patrick Wood
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GKOS Glaukos | Maintains: Underweight | $110 → $72 | $90.82 | -20.72% | 4 | May 6, 2025 | |
| GEHC GE HealthCare Technologies | Maintains: Equal-Weight | $86 → $78 | $70.50 | +10.64% | 6 | May 6, 2025 | |
| BDX Becton, Dickinson and Company | Maintains: Overweight | $280 → $196 | $167.95 | +16.70% | 4 | May 6, 2025 | |
| BLCO Bausch + Lomb | Maintains: Equal-Weight | $18 → $12 | $11.52 | +4.17% | 7 | May 6, 2025 | |
| TFX Teleflex | Maintains: Overweight | $191 → $173 | $126.18 | +37.11% | 5 | May 5, 2025 | |
| BAX Baxter International | Maintains: Underweight | $30 → $28 | $31.20 | -10.26% | 4 | May 5, 2025 | |
| SOLV Solventum | Maintains: Equal-Weight | $73 → $80 | $66.63 | +20.07% | 4 | Mar 5, 2025 | |
| TNDM Tandem Diabetes Care | Downgrades: Equal-Weight | $45 → $22 | $22.74 | -3.25% | 4 | Mar 5, 2025 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $105 → $95 | $54.81 | +73.33% | 2 | Feb 26, 2025 | |
| DXCM DexCom | Maintains: Equal-Weight | $75 → $82 | $85.34 | -3.91% | 7 | Feb 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $70 → $75 | $74.63 | +0.50% | 8 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $120 | $103.29 | +16.18% | 5 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $102 | $82.92 | +23.01% | 5 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $234 → $317 | $257.00 | +23.35% | 5 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $10 | $8.84 | +13.12% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $104 → $145 | $93.20 | +55.58% | 1 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $65 → $85 | $95.88 | -11.35% | 3 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $50 → $37 | $19.55 | +89.26% | 2 | Jul 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $225 → $215 | $225.86 | -4.81% | 3 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $36 | $13.23 | +172.11% | 1 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $143.63 | - | 5 | Dec 11, 2017 |
Glaukos
May 6, 2025
Maintains: Underweight
Price Target: $110 → $72
Current: $90.82
Upside: -20.72%
GE HealthCare Technologies
May 6, 2025
Maintains: Equal-Weight
Price Target: $86 → $78
Current: $70.50
Upside: +10.64%
Becton, Dickinson and Company
May 6, 2025
Maintains: Overweight
Price Target: $280 → $196
Current: $167.95
Upside: +16.70%
Bausch + Lomb
May 6, 2025
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $11.52
Upside: +4.17%
Teleflex
May 5, 2025
Maintains: Overweight
Price Target: $191 → $173
Current: $126.18
Upside: +37.11%
Baxter International
May 5, 2025
Maintains: Underweight
Price Target: $30 → $28
Current: $31.20
Upside: -10.26%
Solventum
Mar 5, 2025
Maintains: Equal-Weight
Price Target: $73 → $80
Current: $66.63
Upside: +20.07%
Tandem Diabetes Care
Mar 5, 2025
Downgrades: Equal-Weight
Price Target: $45 → $22
Current: $22.74
Upside: -3.25%
PROCEPT BioRobotics
Feb 26, 2025
Maintains: Overweight
Price Target: $105 → $95
Current: $54.81
Upside: +73.33%
DexCom
Feb 14, 2025
Maintains: Equal-Weight
Price Target: $75 → $82
Current: $85.34
Upside: -3.91%
Feb 12, 2025
Maintains: Equal-Weight
Price Target: $70 → $75
Current: $74.63
Upside: +0.50%
Feb 6, 2025
Maintains: Overweight
Price Target: $100 → $120
Current: $103.29
Upside: +16.18%
Dec 6, 2024
Maintains: Equal-Weight
Price Target: $104 → $102
Current: $82.92
Upside: +23.01%
Nov 11, 2024
Maintains: Overweight
Price Target: $234 → $317
Current: $257.00
Upside: +23.35%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $18 → $10
Current: $8.84
Upside: +13.12%
Jul 15, 2024
Maintains: Equal-Weight
Price Target: $104 → $145
Current: $93.20
Upside: +55.58%
Jul 15, 2024
Upgrades: Equal-Weight
Price Target: $65 → $85
Current: $95.88
Upside: -11.35%
Jul 15, 2024
Downgrades: Underweight
Price Target: $50 → $37
Current: $19.55
Upside: +89.26%
Dec 4, 2023
Maintains: Equal-Weight
Price Target: $225 → $215
Current: $225.86
Upside: -4.81%
Dec 4, 2023
Initiates: Overweight
Price Target: $36
Current: $13.23
Upside: +172.11%
Dec 11, 2017
Upgrades: Buy
Price Target: n/a
Current: $143.63
Upside: -